Wnt5a is a TLR2/4-ligand that induces tolerance in human myeloid cells.


Journal

Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179

Informations de publication

Date de publication:
2019
Historique:
received: 13 11 2018
accepted: 18 04 2019
entrez: 18 5 2019
pubmed: 18 5 2019
medline: 18 5 2019
Statut: epublish

Résumé

Innate immune responses are rapid, dynamic and highly regulated to avoid overt reactions. This regulation is executed by innate immune tolerance mechanisms that remain obscure. Wnt5a is a signalling protein mainly involved in developmental processes and cancer. The effect of Wnt5a on inflammatory myeloid cells is controversial. Here, we combine primary cell cultures, in vitro binding studies, mass spectrometry and

Identifiants

pubmed: 31098409
doi: 10.1038/s42003-019-0432-4
pii: 432
pmc: PMC6509336
doi:

Substances chimiques

Cytokines 0
Drosophila Proteins 0
IL10 protein, human 0
Intracellular Signaling Peptides and Proteins 0
Ligands 0
NF-kappa B 0
TLR2 protein, human 0
TLR4 protein, human 0
Tl protein, Drosophila 0
Toll-Like Receptor 2 0
Toll-Like Receptor 4 0
Toll-Like Receptors 0
WNT5A protein, human 0
Wnt-5a Protein 0
WntD protein, Drosophila 0
Interleukin-10 130068-27-8

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

176

Déclaration de conflit d'intérêts

The authors declare no competing interests.

Références

J Biol Chem. 2009 Oct 16;284(42):28704-12
pubmed: 19696445
Oncotarget. 2017 Jan 10;8(2):3649-3665
pubmed: 27690299
J Clin Invest. 2015 Sep;125(9):3347-55
pubmed: 26325032
Clin Chest Med. 2008 Dec;29(4):617-25, viii
pubmed: 18954697
J Immunol. 2000 Feb 15;164(4):1940-51
pubmed: 10657644
Blood Adv. 2017 Jul 10;1(16):1274-1286
pubmed: 29296769
Scand J Immunol. 2013 Aug;78(2):194-204
pubmed: 23679576
J Biol Chem. 1995 Apr 21;270(16):9558-63
pubmed: 7721885
Mol Cell Biol. 2006 Aug;26(16):6024-36
pubmed: 16880514
Mol Med. 2012 Dec 06;18:1303-11
pubmed: 22952057
Acta Physiol (Oxf). 2012 Jan;204(1):17-33
pubmed: 21518267
J Neuroinflammation. 2012 May 30;9:111
pubmed: 22647544
Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14978-83
pubmed: 19706447
Clin Cancer Res. 2010 Feb 1;16(3):784-9
pubmed: 20103670
PLoS One. 2015 Jul 28;10(7):e0134492
pubmed: 26218875
Infect Immun. 1999 Apr;67(4):1553-9
pubmed: 10084986
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
pubmed: 12184808
Sci Rep. 2015 Jun 01;5:10536
pubmed: 26030277
DNA Cell Biol. 2017 Jan;36(1):58-66
pubmed: 27828711
Mol Immunol. 2013 Dec;56(4):739-44
pubmed: 23954397
Nucleic Acids Res. 2005 Jan 1;33(Database issue):D562-6
pubmed: 15608262
Methods Mol Biol. 2008;468:131-44
pubmed: 19099251
Immunol Res. 2010 Jul;47(1-3):185-206
pubmed: 20087682
J Immunol. 2012 Jun 1;188(11):5448-58
pubmed: 22547701
Eur J Immunol. 2014 May;44(5):1480-90
pubmed: 24643512
Virulence. 2014 Jan 1;5(1):45-56
pubmed: 24067565
FEBS Lett. 1999 Feb 26;445(2-3):420-4
pubmed: 10094500
J Immunol. 2011 Jun 15;186(12):7243-54
pubmed: 21576504
Mol Cancer. 2014 Apr 26;13:88
pubmed: 24766647
J Immunol. 2011 Oct 15;187(8):4129-39
pubmed: 21918189
J Biol Chem. 1999 Oct 15;274(42):29624-7
pubmed: 10514430
Structure. 2013 Jul 2;21(7):1235-42
pubmed: 23791946
PLoS One. 2011;6(8):e22477
pubmed: 21829626
Nucleic Acids Res. 2006;34(14):3988-99
pubmed: 16914445
Crit Care. 2014 Oct 21;18(5):568
pubmed: 25331176
J Immunol. 2013 Jun 15;190(12):6126-34
pubmed: 23677472
Trends Immunol. 2009 Oct;30(10):475-87
pubmed: 19781994
Nat Protoc. 2006;1(6):2856-60
pubmed: 17406544
Blood. 2006 Aug 1;108(3):965-73
pubmed: 16601243
J Neurochem. 2013 Jun;125(6):803-8
pubmed: 23534675
Nat Commun. 2014 Jul 15;5:4407
pubmed: 25022365
PLoS One. 2017 Jul 6;12(7):e0180025
pubmed: 28683149
Immunol Lett. 2014 Nov;162(1 Pt A):188-99
pubmed: 25196330
PLoS One. 2016 Mar 01;11(3):e0149876
pubmed: 26930594
J Immunol. 2004 May 15;172(10):6185-94
pubmed: 15128806
Immunity. 2008 Aug 15;29(2):182-91
pubmed: 18701082
Nature. 2005 Sep 29;437(7059):746-9
pubmed: 16107793
J Biol Chem. 2006 Sep 8;281(36):26041-50
pubmed: 16835236
Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):504-10
pubmed: 18174455

Auteurs

Meliha Mehmeti (M)

1Cancer Immunology, Department of Translational Medicine, Lund University, Malmö, 21428 Sweden.

Caroline Bergenfelz (C)

1Cancer Immunology, Department of Translational Medicine, Lund University, Malmö, 21428 Sweden.
2Experimental Infection Medicine, Department of Translational Medicine, Lund University, Malmö, 21428 Sweden.

Eva Källberg (E)

1Cancer Immunology, Department of Translational Medicine, Lund University, Malmö, 21428 Sweden.
3Immunology Unit, Department of Experimental Medicine, Lund University, Lund, 22184 Sweden.

Camilla Rydberg Millrud (CR)

1Cancer Immunology, Department of Translational Medicine, Lund University, Malmö, 21428 Sweden.

Per Björk (P)

4Active Biotech AB, Lund, 22007 Sweden.

Fredrik Ivars (F)

3Immunology Unit, Department of Experimental Medicine, Lund University, Lund, 22184 Sweden.

Bengt Johansson-Lindbom (B)

3Immunology Unit, Department of Experimental Medicine, Lund University, Lund, 22184 Sweden.

Sven Kjellström (S)

5Centre of Excellence in Biological and Medical Mass Spectrometry, Lund University, Lund, 22184 Sweden.

Ingemar André (I)

6Center for Molecular Protein Science, Lund University, Lund, 22362 Sweden.

Karin Leandersson (K)

1Cancer Immunology, Department of Translational Medicine, Lund University, Malmö, 21428 Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH